| Autor: |
Das BC; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA.; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Department of Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA., Nandwana NK; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA.; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Das S; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA., Nandwana V; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA., Shareef MA; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA., Das Y; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA., Saito M; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA., Weiss LM; Department of Pathology, Division of Parasitology and Tropical Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA., Almaguel F; School of Medicine, Loma Linda University Health, Loma Linda, CA 92350, USA., Hosmane NS; Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA., Evans T; Department of Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA. |
| Abstrakt: |
A standard goal of medicinal chemists has been to discover efficient and potent drug candidates with specific enzyme-inhibitor abilities. In this regard, boron-based bioactive compounds have provided amphiphilic properties to facilitate interaction with protein targets. Indeed, the spectrum of boron-based entities as drug candidates against many diseases has grown tremendously since the first clinically tested boron-based drug, Velcade. In this review, we collectively represent the current boron-containing drug candidates, boron-containing retinoids, benzoxaboroles, aminoboronic acid, carboranes, and BODIPY, for the treatment of different human diseases.In addition, we also describe the synthesis, key structure-activity relationship, and associated biological activities, such as antimicrobial, antituberculosis, antitumor, antiparasitic, antiprotozoal, anti-inflammatory, antifolate, antidepressant, antiallergic, anesthetic, and anti-Alzheimer's agents, as well as proteasome and lipogenic inhibitors. This compilation could be very useful in the exploration of novel boron-derived compounds against different diseases, with promising efficacy and lesser side effects. |
